Valeant Pharmaceuticals International (NYSE:VRX) (TSX:VRX) and Anacor Pharmaceuticals (NASDAQ:ANAC) have reached a final $142.5 million settlement to put a series of spats to rest, including allegations of intellectual property infringement, shared confidential information, and broken contracts.

Anacor had previously announced a $100 million settlement from Valeant for issues originating from its newly acquired subsidiary Dow Pharmaceutical Sciences, but this latest announcement also includes settlement for dispute over a research and development pact with Valeant business unit Medicis Pharmaceutical.

Valeant's and Anacor's press releases both struck similarly formal tones with no comments from management, although Anacor's delved into more detail on individual issues dating back to 2004.  

Valeant has agreed to pay Anacor its settlement no later than Nov. 8.

Fool contributor Justin Loiseau has no position in any stocks mentioned. You can follow him on Twitter, @TMFJLo, and on Motley Fool CAPS, @TMFJLo.

The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.